Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-091674
Filing Date
2025-09-25
Accepted
2025-09-25 16:30:44
Documents
5
Period of Report
2025-09-25

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0258628-01.htm 6-K 29741
2 ENLIVEX THERAPEUTICS LTD. NOTICE AND PROXY STATEMENT FOR THE ANNUAL GENERAL MEET ea025862801ex99-1_enlivex.htm EX-99.1 175829
3 FORM OF PROXY CARD ea025862801ex99-2_enlivex.htm EX-99.2 8480
4 GRAPHIC tproxy_001.jpg GRAPHIC 1095461
5 GRAPHIC tproxy_002.jpg GRAPHIC 813780
  Complete submission text file 0001213900-25-091674.txt   2845638
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV Israel
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV Israel 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 251344117
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)